Trodelvy (Sacituzumab govitecan), initially developed by Immunomedics (acquired by Gilead), obtained FDA accelerated approval in April 2020 for metastatic triple-negative breast cancer. This Trop‑2-targeted ADC incorporates a 1,2,3-triazole formed via click chemistry within its linker; the triazole offers outstanding chemical stability, enabling controlled antibody-payload conjugation, improving construct homogeneity and boosting overall druggability for clinical application.